Singapore-based NUS Medicine’s Clinical Imaging Research Centre (CIRC), a leading academic centre for advanced molecular imaging, and Cyclotek, one of Australia and New Zealand’s premier radiopharmaceutical manufacturers and distributors, have announced a strategic collaboration to enhance radiopharmaceutical development, clinical trials, and precision diagnostic capability across Singapore and the wider ASEAN region.
The partnership brings together CIRC’s imaging and clinical trial research experience with Cyclotek’s established manufacturing network, GMP and CDMO capabilities. Together, the organisations aim to create a stronger, more connected, and innovation-ready radiopharmaceutical ecosystem that can deliver earlier diagnosis, more accurate disease characterisation, and improved access to next-generation diagnostic and therapeutic agents.
The collaboration will explore opportunities to:
As the collaboration develops, both organisations will also explore future opportunities to support talent development and specialised training in radiopharmaceutical science and advanced molecular imaging, strengthening the long-term workforce capabilities essential for a sustainable regional ecosystem.
The partnership is expected to increase access to PET radiopharmaceuticals for clinical research, support evaluation of emerging diagnostic and therapeutic agents, and improve supply reliability for investigational products. This will aid the earlier detection and characterisation of cancer, neurological diseases, and other serious conditions, contributing to better patient outcomes and improved health system resilience across ASEAN.
Image caption- (Left) Jon Evans, CEO of Cyclotek International and (right) Prof Pek-Lan Khong, Director of the Clinical Imaging Research Centre (CIRC)
